News Archive

Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.

The Asia Pacific Patient Innovation Summit publishes a whitepaper, which serves as a blueprint to help patient organizations improve their approach to sustainable funding, digitalization, and multi-stakeholder partnerships.

As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.

Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.

This year, World Malaria Day is running with the backdrop of countries around the world continuing to fight the COVID-19 pandemic.

Together with local partners, Novartis aims to initiate a watershed development project near its own and supply chain operations in the Telangana region.

The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.

Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.

The first One Young World – Novartis Caucus took place virtually on February 11, 2021.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.